144 - June 2, 2025 | SEC Filings

Brief

Rocket Lab officer Frank Klein filed Form 144 on June 2, 2025, notifying intent to sell 1,818 common shares (value $48,704) acquired via RSU vesting on May 22, 2025. Sales follow recent transactions totaling ~93,436 shares worth ~$2.12M in past 3 months, all under a 10b5-1 plan adopted December 13, 2024. Routine disclosure signals planned diversification, relevant for monitoring insider activity.

Detailed Brief

Form 144 is a notice required under Rule 144 for affiliates like officers selling restricted securities without registration. Here, Rocket Lab Corp. (NASDAQ: RKLB) officer Frank Klein reports proposed sale of 1,818 common shares through Morgan Stanley, with aggregate market value $48,704.22 based on ~461M shares outstanding. Shares stem from RSU vesting on 5/22/2025. Past 3 months: sold 44,885 shares (5/30/2025, $1.2M, 10b5-1), 2,569 (5/28/2025, $77k, 10b5-1), 1,835 (3/17/2025, $37k), and 44,553 (3/14/2025, $810k). Filing relies on Rule 10b5-1 trading plan from 12/13/2024, with Klein certifying no undisclosed material adverse info. This fits Rocket Lab's pattern of equity compensation in space launch sector, where RSU vesting triggers tax-related sales.

Key Telemetry

• Frank Klein (Officer) to sell 1,818 common shares (~$48,704) on ~6/2/2025 via broker Morgan Stanley.

• Shares acquired 5/22/2025 from RSU vesting.

• Past 3 months sales: 93,842 shares total (~$2.12M), including two large 10b5-1 blocks in May.

• 10b5-1 plan adopted 12/13/2024; no material adverse info known.

Impact Vector

Minimal near-term impact for RKLB investors as sale is tiny (~0.0004% of 461M shares outstanding) and pre-planned under 10b5-1 to avoid insider trading concerns, likely for tax or diversification. Strategic non-event amid Rocket Lab's growth in launches/photon; monitor cumulative insider sales and 10-Q/10-K for context on compensation/liquidity. No dilution or distress signals.